HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
CompletedNCT00725075

MK-8435 or placebo for negative symptoms of schizophrenia

About this titleRead the official source — NCT00725075
Medication studyAges 18–55
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: April 10, 2007
Recruitment status
Completed
Enrollment listed in the registry
215
Sponsor
Merck Sharp & Dohme LLC
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Not clearly listed
Age range
From 18 Years to 55 Years
Official registry ID
NCT00725075
Official title
Show the full official title

A Multi-center, Double-blind, Flexible-dose Efficacy Trial With Org 25935 Versus Placebo as add-on Therapy in Subjects With Predominant, Persistent Negative Symptoms of Schizophrenia Treated With a Stable Dose of a Second Generation Antipsychotic (GIANT)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Locations not listed

Checked Official study record (opens in a new tab)
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Merck Sharp & Dohme LLC.

Did this study involve medication?

Yes. The study involved medication, including MK-8435 (Org 25935) 4-8 mg, Placebo and MK-8435 (Org 25935) 12-16 mg.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies